Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 7

1.

miRNA gene promoters are frequent targets of aberrant DNA methylation in human breast cancer.

Vrba L, Muñoz-Rodríguez JL, Stampfer MR, Futscher BW.

PLoS One. 2013;8(1):e54398. doi: 10.1371/journal.pone.0054398. Epub 2013 Jan 16.

2.

DNA methylation of tumor suppressor miRNA genes: a lesson from the miR-34 family.

Wong KY, Yu L, Chim CS.

Epigenomics. 2011 Feb;3(1):83-92. doi: 10.2217/epi.10.74. Review.

PMID:
22126155
3.

Genome-wide epigenetic regulation of miRNAs in cancer.

Baer C, Claus R, Plass C.

Cancer Res. 2013 Jan 15;73(2):473-7. doi: 10.1158/0008-5472.CAN-12-3731. Epub 2013 Jan 10. Review.

4.

MicroRNA epigenetic signatures in human disease.

Piletič K, Kunej T.

Arch Toxicol. 2016 Oct;90(10):2405-19. doi: 10.1007/s00204-016-1815-7. Epub 2016 Aug 24. Review.

PMID:
27557899
5.

Aberrant miRNA promoter methylation and EMT-involving miRNAs in breast cancer metastasis: Diagnosis and therapeutic implications.

Zare M, Bastami M, Solali S, Alivand MR.

J Cell Physiol. 2017 Aug 3. doi: 10.1002/jcp.26116. [Epub ahead of print] Review.

PMID:
28771724
6.

Disruption of the expression and function of microRNAs in lung cancer as a result of epigenetic changes.

Watanabe K, Takai D.

Front Genet. 2013 Dec 3;4:275. doi: 10.3389/fgene.2013.00275. Review.

7.

The pharmacoepigenetics of drug metabolism and transport in breast cancer: review of the literature and in silico analysis.

Nasr R, Sleiman F, Awada Z, Zgheib NK.

Pharmacogenomics. 2016 Sep;17(14):1573-85. doi: 10.2217/pgs-2016-0081. Epub 2016 Aug 26. Review.

PMID:
27561648

Supplemental Content

Support Center